2022 - Research.com Immunology in Netherlands Leader Award
His scientific interests lie mostly in Antibody, Monoclonal antibody, Virology, Immunology and Epitope. His Antibody study incorporates themes from Molecular biology, Antigen and In vivo. Paul W. H. I. Parren has researched Monoclonal antibody in several fields, including Ebolavirus and Cytotoxicity.
His Virology study integrates concerns from other disciplines, such as Peptide library and Phage display. His Immunology research focuses on Cancer research and how it connects with Immunotherapy, Growth factor receptor, Mechanism of action and Ex vivo. His Epitope research includes elements of Viral envelope, Glycoprotein and Complementarity determining region.
Paul W. H. I. Parren mostly deals with Antibody, Immunology, Monoclonal antibody, Molecular biology and Virology. His studies deal with areas such as Cancer research, Antigen and Cytotoxicity as well as Antibody. Paul W. H. I. Parren conducts interdisciplinary study in the fields of Monoclonal antibody and Diagnostic methods through his works.
His biological study spans a wide range of topics, including Cell culture, T cell, Biochemistry, Complement-dependent cytotoxicity and Primary and secondary antibodies. In his work, Immunoglobulin G is strongly intertwined with Cell biology, which is a subfield of Complement system. He has researched Epitope in several fields, including Viral envelope and Binding site.
Paul W. H. I. Parren spends much of his time researching Antibody, Cancer research, Cytotoxicity, Immunology and Monoclonal antibody. His Antibody research is multidisciplinary, incorporating elements of Cell, Molecular biology and Antigen. His Molecular biology study incorporates themes from Cell biology, Complement system and Cancer immunotherapy.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Cancer, Immunotherapy, In vitro and In vivo. His work carried out in the field of Immunology brings together such families of science as Computational biology, Rodent and Neoplasms therapy. In his research, Degranulation is intimately related to Chronic lymphocytic leukemia, which falls under the overarching field of Monoclonal antibody.
His primary areas of study are Cancer research, Antibody, Immunology, Immunotherapy and Daratumumab. The various areas that Paul W. H. I. Parren examines in his Cancer research study include Receptor tyrosine kinase, In vivo and Cytotoxicity. In the subject of general Antibody, his work in Immunoglobulin G is often linked to Proteases, thereby combining diverse domains of study.
His studies in Immunotherapy integrate themes in fields like Relapsed refractory, Multiple myeloma and Fc-Gamma Receptor. His Daratumumab research incorporates elements of Tumor microenvironment, Antibody-dependent cell-mediated cytotoxicity, Peripheral blood mononuclear cell, CD38 and Leukemia. His Monoclonal antibody research is multidisciplinary, incorporating perspectives in Cancer cell, Cell culture and Antigen, CD20.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
Dennis R. Burton;Jayashree Pyati;Raju Koduri;Stephen J. Sharp.
The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless.
Frans Rijsewijk;Marcus Schuermann;Els Wagenaar;Paul Parren.
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Erica Ollmann Saphire;Paul W. H. I. Parren;Ralph Pantophlet;Michael B. Zwick.
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
Michael B. Zwick;Aran F. Labrijn;Meng Wang;Catherine Spenlehauer.
Journal of Virology (2001)
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
Marijn van der Neut Kolfschoten;Janine Schuurman;Mario Losen;Wim K. Bleeker.
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell;Lars Hangartner;Meredith Hunter;Carin E. G. Havenith.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker.
Journal of Immunology (2011)
Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro
Paul W. H. I. Parren;Preston A. Marx;Preston A. Marx;Ann J. Hessell;Amara Luckay.
Journal of Virology (2001)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Jessica L. Teeling;Wendy J.M. Mackus;Luus J.J.M. Wiegman;Jeroen H.N. van den Brakel.
Journal of Immunology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: